In 2023, Novo paid 62% of its gross sales back in rebates across its sales. Of roughly $88.3 billion in gross sales, about $32 billion was paid back in rebates to Medicare and U.S. managed care plans.

Just last week, Novo’s chief rival Eli Lilly reported $3.11 billion in sales of its diabetes GLP-1 Mounjaro, falling well short of analysts’ $3.7 billion estimate. The story was much the same ...

Hims generated roughly $200–225 million in 2024 from its GLP-1 business — a massive chunk of its $1.48 billion in revenue. But Novo Nordisk just nuked that rocket mid-flight.

Novo Nordisk also said 62.9% of patients in the Wegovy group achieved resolution of the fatty liver disease with no worsening of liver fibrosis. By comparison, 34.1% of those in the placebo group ...

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.

Liraglutide, a GLP-1 medication marketed by Novo Nordisk as the weight-loss drug Saxenda and the diabetes treatment Victoza, produced an average reduction in body mass index of 5.8% among 6- to 11 ...

Novo has become a household name thanks to semaglutide, the once-weekly GLP-1 agonist that is marketed as Ozempic and Wegovy for diabetes and obesity, respectively. The Danish Big Pharma had been ...

Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline.

In 2022, Novo Nordisk generated roughly $25 billion in sales. According to management, the company's total revenue for 2023 is expected to increase between 32% and 38% year over year.

Novo Integrated Sciences Inc. NVOS shares more than doubled in the extended session Thursday after the tiny healthcare company said it or entered a $1 billion funding agreement for the next 15 years.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1.